- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02763319
A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) (B-MIND)
A Phase 2/3, Randomised, Multicentre Study of Tafasitamab With Bendamustine Versus Rituximab With Bendamustine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Adelaide, Australia, 5000
- MorphoSys Research Site
-
Albury, Australia, 2640
- MorphoSys Research Site
-
Bedford Park, Australia, 5042
- MorphoSys Research Site
-
Box Hill, Australia, 3128
- MorphoSys Research Site
-
Concord, Australia, 2139
- MorphoSys Research Site
-
Frankston, Australia, 3199
- MorphoSys Research Site
-
Garran, Australia, 2605
- MorphoSys Research Site
-
Geelong, Australia, 3220
- MorphoSys Research Site
-
Gosford, Australia, 2250
- MorphoSys Research Site
-
Nedlands, Australia, 6009
- MorphoSys Research Site
-
South Brisbane, Australia, 4101
- MorphoSys Research Site
-
St. Albans, Australia, 3021
- MorphoSys Research Site
-
-
-
-
-
Innsbruck, Austria, 6020
- MorphoSys Research Site
-
-
-
-
-
Saskatoon, Canada, S7N4H4
- MorphoSys Research Site
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 1Z2
- MorphoSys Research Site
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3E 0V9
- MorphoSys Research Site
-
-
New Brunswick
-
Saint John, New Brunswick, Canada, E2L 4L2
- MorphoSys Research Site
-
-
Newfoundland and Labrador
-
Saint John's, Newfoundland and Labrador, Canada, A1B 3V6
- MorphoSys Research Site
-
-
Ontario
-
Kingston, Ontario, Canada, K7L 5P9
- MorphoSys Research Site
-
-
Quebec
-
Greenfield Park, Quebec, Canada, J4V 2H1
- MorphoSys Research Site
-
Montréal, Quebec, Canada, H1T 2M4
- MorphoSys Research Site
-
-
-
-
-
Zagreb, Croatia, 10000
- MorphoSys Research Site
-
-
-
-
-
Hradec Kralove, Czechia, 50005
- MorphoSys Research Site
-
Olomouc, Czechia, 77900
- MorphoSys Research Site
-
Prague, Czechia, 12808
- MorphoSys Research Site
-
Prague, Czechia, 15006
- MorphoSys Research Site
-
-
-
-
-
Oulu, Finland, 90220
- MorphoSys Research Site
-
Tampere, Finland, 33521
- MorphoSys Research Site
-
-
-
-
-
Grenoble, France, 38043
- MorphoSys Research Site
-
Le Mans, France, 72037
- MorphoSys Research Site
-
-
-
-
-
Aachen, Germany, 52074
- MorphoSys Research Site
-
Berlin, Germany, 10967
- MorphoSys Research Site
-
Berlin, Germany, 12351
- MorphoSys Research Site
-
Düsseldorf, Germany, 40479
- MorphoSys Research Site
-
Giessen, Germany, 35392
- MorphoSys Research Site
-
Homburg, Germany, 66421
- MorphoSys Research Site
-
Leipzig, Germany, 04103
- MorphoSys Research Site
-
Mainz, Germany, 55131
- MorphoSys Research Site
-
Munich, Germany, 81377
- MorphoSys Research Site
-
Munich, Germany, 81737
- MorphoSys Research Site
-
Mutlangen, Germany, 73557
- MorphoSys Research Site
-
Münster, Germany, 48149
- MorphoSys Research Site
-
Rostock, Germany, 18057
- MorphoSys Research Site
-
Stuttgart, Germany, 70199
- MorphoSys Research Site
-
Stuttgart, Germany, 70376
- MorphoSys Research Site
-
Traunstein, Germany, 83278
- Morphosys
-
-
-
-
-
Budapest, Hungary, 1083
- Morphosys
-
Debrecen, Hungary, 4032
- MorphoSys Research Site
-
Győr, Hungary, 9024
- MorphoSys Research Site
-
Szeged, Hungary, 6725
- Morphosys
-
-
-
-
-
Haifa, Israel, 31096
- MorphoSys Research Site
-
Jerusalem, Israel, 90131
- MorphoSys Research Site
-
Jerusalem, Israel, 91120
- MorphoSys Research Site
-
Kfar Saba, Israel, 44281
- MorphoSys Research Site
-
Tel Aviv, Israel, 69710
- MorphoSys Research Site
-
-
-
-
-
Alessandria, Italy, 15121
- MorphoSys Research Site
-
Bologna, Italy, 40138
- MorphoSys Research Site
-
Campobasso, Italy, 86100
- MorphoSys Research Site
-
Cona, Italy, 44124
- MorphoSys Research Site
-
Genova, Italy, 16132
- MorphoSys Research Site
-
Lecce, Italy, 73100
- MorphoSys Research Site
-
Meldola, Italy, 47014
- MorphoSys Research Site
-
Monza, Italy, 20900
- MorphoSys Research Site
-
Napoli, Italy, 80131
- MorphoSys Research Site
-
Novara, Italy, 28100
- MorphoSys Research Site
-
Orbassano, Italy, 10043
- MorphoSys Research Site
-
Parma, Italy, 43100
- MorphoSys Research Site
-
Pavia, Italy, 27100
- MorphoSys Research Site
-
Pisa, Italy, 56126
- MorphoSys Research Site
-
Ravenna, Italy, 48121
- MorphoSys Research Site
-
Reggio Emilia, Italy, 42100
- MorphoSys Research Site
-
Rimini, Italy, 47923
- MorphoSys Research Site
-
Rome, Italy, 00128
- MorphoSys Research Site
-
Rome, Italy, 00144
- MorphoSys Research Site
-
Terni, Italy, 05100
- MorphoSys Research Site
-
Turin, Italy, 10043
- MorphoSys Research Site
-
Turin, Italy, 10126
- MorphoSys Research Site
-
-
-
-
-
Busan, Korea, Republic of, 49201
- MorphoSys Research Site
-
Goyang-si, Korea, Republic of, 10408
- MorphoSys Research Site
-
Incheon, Korea, Republic of, 21565
- MorphoSys Research Site
-
Jeonju, Korea, Republic of, 54907
- MorphoSys Research Site
-
Seongnam, Korea, Republic of, 13620
- MorphoSys Research Site
-
Seoul, Korea, Republic of, 03722
- MorphoSys Research Site
-
Seoul, Korea, Republic of, 05505
- MorphoSys Research Site
-
Seoul, Korea, Republic of, 07985
- MorphoSys Research Site
-
Seoul, Korea, Republic of, 135710
- MorphoSys Research Site
-
Ulsan, Korea, Republic of, 44033
- MorphoSys Research Site
-
-
-
-
-
Addington, New Zealand, 8011
- MorphoSys Research Site
-
Auckland, New Zealand, 2025
- MorphoSys Research Site
-
Grafton, New Zealand, 1148
- MorphoSys Research Site
-
-
-
-
-
Bydgoszcz, Poland, 85-796
- MorphoSys Research Site
-
Gdynia, Poland, 81-519
- MorphoSys Research Site
-
Kraków, Poland, 30-510
- MorphoSys Research Site
-
Legnica, Poland, 59-220
- MorphoSys Research Site
-
Lodz, Poland, 93-510
- MorphoSys Research Site
-
Lublin, Poland, 20-090
- MorphoSys Research Site
-
Warszawa, Poland, 02781
- MorphoSys Research Site
-
Wrocław, Poland, 50-556
- MorphoSys Research Site
-
-
-
-
-
Braga, Portugal, 4710243
- MorphoSys Research Site
-
Coimbra, Portugal, 3000-075
- MorphoSys Research Site
-
Coimbra, Portugal, 3000075
- MorphoSys Research Site
-
Matosinhos, Portugal, 4464-504
- MorphoSys Research Site
-
Porto, Portugal, 4099001
- MorphoSys Research Site
-
Porto, Portugal, 4200072
- MorphoSys Research Site
-
Pragal, Portugal, 2901-951
- MorphoSys Research Site
-
-
-
-
-
Bucharest, Romania, 022328
- MorphoSys Research Site
-
Bucharest, Romania, 30171
- MorphoSys Research Site
-
Iaşi, Romania, 700483
- MorphoSys Research Site
-
-
-
-
-
Belgrade, Serbia, 11000
- MorphoSys Research Site
-
Kragujevac, Serbia, 34000
- MorphoSys Research Site
-
-
-
-
-
Singapore, Singapore, 119074
- MorphoSys Research Site
-
Singapore, Singapore, 169610
- MorphoSys Research Site
-
Singapore, Singapore, 188770
- MorphoSys Research Site
-
Singapore, Singapore, 258499
- MorphoSys Research Site
-
-
-
-
-
Cadiz, Spain, 11009
- MorphoSys Research Site
-
Girona, Spain, 17007
- MorphoSys Research Site
-
L'Hospitalet De Llobregat, Spain, 08908
- MorphoSys Research Site
-
Madrid, Spain, 28007
- MorphoSys Research Site
-
Madrid, Spain, 28023
- MorphoSys Research Site
-
Madrid, Spain, 28050
- MorphoSys Research Site
-
Palma de Mallorca, Spain, 07198
- MorphoSys Research Site
-
Pamplona, Spain, 31008
- MorphoSys Research Site
-
Pozuelo De Alarcón, Spain, 28223
- MorphoSys Research Site
-
Sabadell, Spain, 08208
- Morphosys
-
Salamanca, Spain, 37007
- MorphoSys Research Site
-
Valencia, Spain, 46940
- MorphoSys Research Site
-
-
-
-
-
Chang Hua, Taiwan, 50006
- MorphoSys Research Site
-
Hualien City, Taiwan, 97002
- MorphoSys Research Site
-
Taichung City, Taiwan, 40447
- MorphoSys Research Site
-
-
-
-
-
Adana, Turkey, 01330
- MorphoSys Research Site
-
Ankara, Turkey, 06500
- MorphoSys Research Site
-
Ankara, Turkey, 06590
- MorphoSys Research Site
-
Bornova, Turkey, 35100
- MorphoSys Research Site
-
Gaziantep, Turkey, 27310
- MorphoSys Research Site
-
Manisa, Turkey, 45010
- MorphoSys Research Site
-
Samsun, Turkey, 55139
- MorphoSys Research Site
-
İzmir, Turkey, 35340
- MorphoSys Research Site
-
-
-
-
-
Birmingham, United Kingdom, B71 4HJ
- MorphoSys Research Site
-
Leeds, United Kingdom, LS97 TF
- MorphoSys Research Site
-
Southend on Sea, United Kingdom, SS0 0RY
- MorphoSys Research Site
-
-
-
-
California
-
Anaheim, California, United States, 92801
- MorphoSys Research Site
-
Bakersfield, California, United States, 93309
- MorphoSys Research Site
-
Burbank, California, United States, 91505
- MorphoSys Research Site
-
Fresno, California, United States, 93701
- MorphoSys Research Site
-
Los Angeles, California, United States, 90017
- MorphoSys Research Site
-
Whittier, California, United States, 90603
- MorphoSys Research Site
-
-
Connecticut
-
Plainville, Connecticut, United States, 06062
- MorphoSys Research Site
-
-
Illinois
-
Skokie, Illinois, United States, 60077
- MorphoSys Research Site
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- MorphoSys Research Site
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- MorphoSys Research Site
-
-
Mississippi
-
Hattiesburg, Mississippi, United States, 39401
- MorphoSys Research Site
-
Jackson, Mississippi, United States, 39126
- MorphoSys Research Site
-
-
New Jersey
-
Morristown, New Jersey, United States, 07960
- MorphoSys Research Site
-
-
New York
-
New York, New York, United States, 10029
- MorphoSys Research Site
-
Stony Brook, New York, United States, 11794
- MorphoSys Research Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73142-2015
- MorphoSys Research Site
-
-
Tennessee
-
Knoxville, Tennessee, United States, 37909
- MorphoSys Research Site
-
-
Texas
-
Lubbock, Texas, United States, 79415
- MorphoSys Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
INCLUSION CRITERIA:
- Age ≥18 years
- Histologically confirmed diagnosis, according to the World Health Organization (WHO, 2008) classification, of: DLBCL NOS, THRLBCL, EBV-positive DLBCL, composite lymphoma with a DLBCL component with a DLBCL relapse subsequent to DLBCL treatment, disease transformed from an earlier diagnosis of low grade lymphoma (i.e. an indolent pathology such as follicular lymphoma, marginal zone lymphoma) into DLBCL with a DLBCL relapse subsequent to DLBCL treatment.
- Fresh tumour tissue for central pathology review must be provided as an adjunct to participation in this study. Should it not be possible to obtain a fresh tumour tissue sample, archival paraffin embedded tumour tissue acquired ≤3 years prior to screening for this protocol must be available for this purpose.
Patients must have:
- relapsed or refractory DLBCL
- at least one bidimensionally measurable disease site. The lesion must have a greatest transverse diameter of ≥1.5 cm and greatest perpendicular diameter of ≥1.0 cm at baseline. The lesion must be positive on PET scan
- received at least one, but no more than three previous systemic therapy lines for the treatment of DLBCL. At least one previous therapy line must have included a CD20-targeted.
- ECOG 0 to 2
- Patients after failure of ASCT or patients considered in the opinion of the investigator currently not eligible for HDC with subsequent ASCT.
Patients must meet the following laboratory criteria at Screening:
- ANC ≥1.5 × 109/L (unless secondary to bone marrow involvement by DLBCL)
- PLTs ≥90 × 109/L (unless secondary to bone marrow involvement by DLBCL) and absence of active bleeding
- total serum bilirubin ≤2.5 × ULN unless secondary to Gilbert's syndrome (or pattern consistent with Gilbert's) or documented liver involvement by lymphoma. Patients with Gilbert's syndrome or documented liver involvement by lymphoma may be included if their total bilirubin is ≤5 x ULN
- ALT, AST and AP ≤3 × ULN or <5 × ULN in cases of documented liver involvement by lymphoma
- serum creatinine ≤2.0 x ULN or creatinine clearance must be ≥40 mL/min calculated using a standard Cockcroft-Gault formula (Cockroft & Gault, 1976)
- For a female of childbearing potential (FCBP), a negative pregnancy test must be confirmed before enrolment. An FCBP must commit to take highly effective contraceptive precautions without interruption during the study and for 3, 6 or 12 months after the last dose of Tafasitamab, BEN or RTX respectively, whichever is later. An FCBP must refrain from breastfeeding and donating blood or oocytes during the course of the study and for 3, 6 or 12 months after the last dose of Tafasitamab, BEN or RTX respectively, whichever is later. Restrictions concerning blood donations apply as well to females who are not of childbearing potential.
- Males must use an effective barrier method of contraception without interruption during the study and for 3, 6 or 12 months after the last dose of Tafasitamab, BEN or RTX respectively, whichever is later, if the patient is sexually active with an FCBP. Males must refrain from donating blood or sperm during study participation and for 3, 6 or 12 months after the last dose of Tafasitamab, BEN or RTX respectively, whichever is later.
In the opinion of the investigator, the patients must:
- be able to comply with all study-related procedures, medication use, and evaluations
- be able to understand and give informed consent
- not be considered to be potentially unreliable and/or not cooperative.
EXCLUSION CRITERIA:
- Patients who have: any other histological type of lymphoma including, e.g., primary mediastinal (thymic) large B-cell lymphoma (PMBL) or Burkitt's lymphoma, primary refractory DLBCL, patients with known "double/triple hit" DLBCL genetics, CNS lymphoma involvement in present or past medical history
- Patients who had a major surgery less than 30 days prior to Day 1 dosing
Patients who have, within 14 days prior to Day 1 dosing:
- not discontinued CD20-targeted therapy, chemotherapy, radiotherapy, investigational anticancer therapy or other lymphoma-specific therapy
- received live vaccines
- required parenteral antimicrobial therapy for active, intercurrent systemic infections
Patients who:
- in the opinion of the investigator, have not recovered sufficiently from the adverse toxic effects of prior therapies, major surgeries or significant traumatic injuries
- were previously treated with CD19-targeted therapy or BEN
- have a history of previous severe allergic reactions to compounds of similar biological or chemical composition to Tafasitamab, RTX, murine proteins or BEN, or the excipients contained in the study drug formulations
- have undergone ASCT within a period of ≤3 months prior to signing the informed consent form. Patients who have a more distant history of ASCT must exhibit full haematological recovery before enrolment into the study.
- have undergone previous allogeneic stem cell transplantation
- concurrently use other anticancer or experimental treatments
Prior history of malignancies other than DLBCL, unless the patient has been free of the disease for ≥3 years prior to Screening. Exceptions to the ≥3-year time limit include history of the following:
- basal cell carcinoma of the skin
- squamous cell carcinoma of the skin
- carcinoma in situ of the cervix, breast and bladder
f) incidental histological finding of prostate cancer (Tumour/Node/Metastasis [TNM] stage of T1a or T1b)
Patients with:
- positive hepatitis B and/or C serology
- known seropositivity for or history of active viral infection with HIV
- evidence of active, severe uncontrolled systemic infections or sepsis
- a history or evidence of severely immunocompromised state
- a history or evidence of severe hepatic impairment (total serum bilirubin > 3 mg/dL), jaundice unless secondary to Gilbert's syndrome or documented liver involvement by lymphoma
- a history or evidence of clinically significant cardiovascular, cerebrovascular, CNS and/or other disease that, in the investigator's opinion, would preclude participation in the study or compromise the patient's ability to give informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tafasitamab and bendamustine
|
Tafasitamab: Tafasitamab dose: 12 mg/kg intravenously (IV)
Other Names:
|
Active Comparator: Rituximab and bendamustine
|
Other Names:
Rituximab: Dose: 375 mg/m2 IV
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival (PFS)
Time Frame: From date of randomization until recurrence/disease progression, unacceptable toxicity, death or discontinuation for any other reason, whichever comes first assessed up to 4 yrs
|
To determine the efficacy of a combination of MOR00208 with BEN versus a combination of RTX with BEN in terms of progression-free survival (PFS) in:
|
From date of randomization until recurrence/disease progression, unacceptable toxicity, death or discontinuation for any other reason, whichever comes first assessed up to 4 yrs
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate (ORR)
Time Frame: From date of randomization assessed up to 4 yrs
|
To determine efficacy
|
From date of randomization assessed up to 4 yrs
|
Duration of response (DoR)
Time Frame: From date of randomization assessed up to 4 yrs
|
To determine efficacy
|
From date of randomization assessed up to 4 yrs
|
overall survival (OS)
Time Frame: From date of randomization assessed up to 4 yrs
|
To determine efficacy
|
From date of randomization assessed up to 4 yrs
|
disease control rate (DCR)
Time Frame: From date of randomization assessed up to 4 yrs
|
To determine efficacy
|
From date of randomization assessed up to 4 yrs
|
time to progression (TTP)
Time Frame: From date of randomization assessed up to 4 yrs
|
To determine efficacy
|
From date of randomization assessed up to 4 yrs
|
time to next treatment (TTNT)
Time Frame: From date of randomization assessed up to 4 yrs
|
To determine efficacy
|
From date of randomization assessed up to 4 yrs
|
Number of patients with adverse events
Time Frame: assessed up to 4 yrs
|
Number of participants with treatment- and non-treatment related adverse events as assessed by CTCAE
|
assessed up to 4 yrs
|
quality of life (QoL)
Time Frame: assessed up to 4 yrs
|
EORTC QLQ-C30 and EQ-5D-5L questionnaires will be used
|
assessed up to 4 yrs
|
Number of patients developing Tafasitamab antibodies
Time Frame: assessed up to 2 yrs
|
assessed up to 2 yrs
|
|
Maximum Plasma Concentration of Tafasitamab (Cmax)
Time Frame: assessed up to 2 yrs
|
assessed up to 2 yrs
|
|
Apparent trough concentration (Cpd) of Tafsitamab
Time Frame: assessed up to 2 yrs
|
assessed up to 2 yrs
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antineoplastic Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Antineoplastic Agents, Immunological
- Bendamustine Hydrochloride
- Rituximab
Other Study ID Numbers
- MOR208C204
- 2014-004689-11 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diffuse Large B-cell Lymphoma
-
Memorial Sloan Kettering Cancer CenterRecruitingLymphoma | Lymphoma, B-Cell | DLBCL - Diffuse Large B Cell Lymphoma | Large B-cell Lymphoma | Large-cell Lymphoma | Mediastinal B-Cell Diffuse Large Cell LymphomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); AmgenActive, not recruitingRecurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | CD20 Positive | Stage I Diffuse Large B-Cell Lymphoma | Stage II Diffuse Large B-Cell Lymphoma | Stage III Diffuse Large B-Cell Lymphoma | Stage IV Diffuse Large B-Cell LymphomaUnited States
-
University Hospital Southampton NHS Foundation...Hoffmann-La RocheTerminatedDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaUnited Kingdom
-
National Cancer Institute (NCI)WithdrawnDiffuse, Large B-cell Lymphoma | Lymphoma, Diffuse Large-Cell | Lymphoma, Diffuse Large-Cell B-cell | Large-Cell Lymphoma, Diffuse
-
Qian WenbinNot yet recruitingDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaChina
-
Dana-Farber Cancer InstituteBayer; AbbVieActive, not recruitingDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaUnited States
-
Memorial Sloan Kettering Cancer CenterSanofi; Columbia University; Medical College of Wisconsin; University of Rochester and other collaboratorsActive, not recruitingDiffuse Large B-cell Lymphoma (DLBCL) | Relapsed Diffuse Large B-cell Lymphoma (DLBCL) | Refractory Diffuse Large B-cell Lymphoma (DLBCL)United States
-
Autolus LimitedCompletedDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | DLBCL | Relapsed Diffuse Large B-Cell LymphomaUnited States, United Kingdom
-
Herlev HospitalOdense University Hospital; Zealand University Hospital; Aarhus University Hospital and other collaboratorsCompletedDiffuse Large B-cell Lymphoma Recurrent | Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Cell of Origin
-
UNC Lineberger Comprehensive Cancer CenterCephalonCompletedLymphoma | Diffuse Large B-Cell Lymphoma | Lymphoma, Diffuse Large-Cell | Diffuse Large-Cell LymphomaUnited States
Clinical Trials on Tafasitamab
-
University Hospital TuebingenRecruitingALL, Childhood B-Cell | Acute Lymphoid Leukemia Relapse | Acute Lymphocytic Leukemia RefractoryGermany
-
MorphoSys AGIqvia Pty LtdRecruitingDiffuse Large B-cell LymphomaUnited States
-
Incyte CorporationActive, not recruitingChronic Lymphocytic Leukemia | Non Hodgkin LymphomaUnited States, Spain, France, Italy, Belgium, Germany, Austria
-
MorphoSys AGCompletedDiffuse Large B-cell LymphomaBelgium, Germany, United States, Austria, Czechia, France, Italy, Portugal, Spain
-
International Extranodal Lymphoma Study Group (IELSG)Active, not recruitingMarginal Zone LymphomaItaly, Switzerland, Austria
-
Alvaro Alencar, MDIncyte Corporation; BeiGene; MorphoSys AGNot yet recruiting
-
Memorial Sloan Kettering Cancer CenterIncyte CorporationRecruitingMantle Cell Lymphoma | MCLUnited States
-
Zhao WeiliNot yet recruitingDiffuse Large B-cell LymphomaChina
-
James RubensteinIncyte CorporationRecruitingPrimary Central Nervous System Lymphoma | CNS Lymphoma | Secondary Central Nervous System LymphomaUnited States
-
MorphoSys AGRecruitingDiffuse Large B Cell LymphomaKorea, Republic of, Czechia, Spain, Israel, Italy, Austria, Poland, United States, France